Cognito Therapeutics has raised a $73M Series B funding round to develop therapies for Alzheimer's and other central nervous system diseases.
The company has raised $93M so far.
- FoundersX
Ventures led the round, with participation from Alzheimer's Drug
Discovery Foundation, Starbloom Capital, IAG Capital, and WS Investment
Company.
- The company aims to use the funds to continue
researching the use of its neuromodulation device. The latter delivers
proprietary gamma frequency light and sound stimulation that the company
hopes will help treat Alzheimer's Disease.
- Its clinical trial process is currently enrolling 500 patients across 50 clinics across the U.S.
- The company is based in Cambridge, Massachusetts.
- Cognito was founded in 2016.
